Author

J. M. Richner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 6 Organism:mouse· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. K. Pinto· 2 shared J. Class· 2 shared J. D. Brien· 2 shared M. C. Richner· 2 shared P. Penaloza-MacMaster· 2 shared S. Sanchez· 2 shared T. Dangi· 2 shared A. Dickson· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. K. Pinto

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Type I IFN stimulates lymph node stromal cells from adult and old mice during a West Nile virus infection

A. K. Bennett, M. Richner, M. D. Mun, J. M. Richner

This study investigates age-related differences in lymph node stromal cell responses to West Nile virus infection in adult and old mice, finding altered gene expression and immune function in aged cells.

bioRxiv · Jan 5, 2023Immunology

Pre-existing immunity modulates responses to mRNA boosters

T. Dangi, S. Sanchez, M. H. Lew, L. Visvabharathy, J. M. Richner, I. Koralnik, P. Penaloza-MacMaster

The paper shows pre-existing immunity affects the effectiveness of mRNA vaccine boosters, with lower pre-existing antibodies leading to greater post-booster increases and updated vaccines being more effective in certain serostatus groups.

bioRxiv · Jun 27, 2022Immunology

Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2

T. Dangi, S. Sanchez, M. Park, J. Class, M. C. Richner, J. M. Richner, P. Penaloza-MacMaster

This study shows that nucleocapsid-specific antibodies can help control SARS-CoV-2 infection in mice, suggesting their potential inclusion in vaccines and monoclonal therapies.

bioRxiv · Mar 9, 2022 · PreprintImmunology

Dual Inhibition of Cathepsin L and 3CL-Pro by GC-376 Constrains SARS Cov2 Infection Including Omicron Variant

B. S. Prabhakar, P. Kumar, K. Ratia, J. M. Richner, G. R. J. Thatcher, R. Kadam, S. P. Smieszek, B. P. Przychodzen, V. Koprivica, G. Birznieks, M. H. Polymeropoulos

This study shows that dual inhibition of cathepsin-L and 3CL-Pro by GC-376 effectively inhibits SARS-CoV-2 infection, including the Omicron variant, in highly susceptible cell lines.

bioRxiv · Feb 9, 2022 · PreprintMicrobiology

A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity

C. J. Wollner, M. C. Richner, M. A. Hassert, A. K. Pinto, J. D. Brien, J. M. Richner

This paper develops an mRNA-LNP vaccine against Dengue Virus serotype 1 that elicits strong, serotype-specific immunity with reduced antibody-dependent enhancement.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology

mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2

M. Hassert, E. Geerling, E. T. Stone, T. L. Steffen, A. Dickson, M. S. Feldman, J. Class, J. M. Richner, J. D. Brien, A. K. Pinto

This study uses mRNA to express human ACE2 in mice to study SARS-CoV-2 adaptive immune responses, finding enhanced T cell responses but no antibody enhancement.

bioRxiv · Aug 7, 2020Immunology